Login to Your Account

Karo Bio Rakes in $80M for Eprotirome Development

By Cormac Sheridan

Wednesday, October 27, 2010
With the start of pivotal Phase III clinical trials for eprotirome looming, Karo Bio AB has secured SEK530 million (US$79.7 million) to fund the research, by raising SEK300 million in a forthcoming rights issue that is fully guaranteed and another SEK230 million in an equity-based credit facility. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription